Drug
Sparc1104 Modified Dose Regimen I
Sparc1104 Modified Dose Regimen I: highest development phase Phase 3, developed by Sun Pharma. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Sun Pharma
Trials
| Drug | Phase | Indication |
|---|---|---|
| SPARC1104 modified dose regimen I NCT01797185 | Phase 3 | Spasticity |
Latest
No recent events.
Follow Sparc1104 Modified Dose Regimen I on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.